1. Overview and Indications

Dimethyl fumarate (DMF), marketed under the brand name Tecfidera, is an FDA-approved disease-modifying therapy (DMT) for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). Its use is supported by robust clinical evidence demonstrating efficacy in reducing relapse rates and delaying disability progression.

2. Mechanism of Action

The precise mechanism of DMF remains incompletely understood, but its therapeutic effects are attributed to two key pathways:

• Activation of the Nrf2 Pathway:
  Upon ingestion, DMF is metabolized to its active thiol compound, monomethyl fumarate (MMF). MMF induces oxidative stress in microglia and astrocytes, triggering the translocation of Nuclear factor erythroid 2-related factor 2 (Nrf2) into the nucleus. This upregulates antioxidant response elements (AREs), enhancing endogenous antioxidant defenses (e.g., glutathione synthesis). This mitigates oxidative damage, a central driver of MS pathology.
• Nicotinic Acid Receptor Agonism:
  MMF also acts as an agonist at GPR132, a G-protein-coupled receptor (GPCR) expressed on immune cells. This interaction modulates T-cell responses and reduces pro-inflammatory cytokine production (e.g., TNF-α, IL-17), though the clinical significance of this effect remains under investigation.

Evidence: Preclinical studies highlight Nrf2 activation as a critical neuroprotective mechanism, while clinical trials confirm its role in reducing inflammatory markers (e.g., C-reactive protein).

3. Dosing and Administration

• Initiation:
  Start with 120 mg twice daily for 7 days to induce tolerance, followed by titration to 240 mg twice daily. This gradual approach minimizes gastrointestinal (GI) side effects.
• Administration:
  Capsules must be swallowed whole; crushing or chewing may reduce bioavailability and increase irritation risk. Avoid exposure to light during storage.

Pharmacist Note: Counsel patients on adherence to dosing schedules and the importance of gradual titration to improve tolerability.

4. Efficacy in MS Subtypes

• Relapsing-Remitting MS (RRMS):
  Clinical trials (e.g., MELLODDY trial, 2015) demonstrated reduced annualized relapse rate (ARR) by 44% and delayed progression to disability compared to interferon beta-1a. It is also effective in CIS.
• Active Secondary Progressive MS (SPMS):
  Approved in 2018 based on the ORATORIO trial, which showed reduced risk of sustained physical disability progression (HR 0.62; 95% CI 0.43–0.90).
• Neuroprotection:
  Long-term use may confer neuroprotective benefits via Nrf2-mediated mechanisms, though this requires further validation.

5. Adverse Effects and Safety Monitoring

Common Side Effects (≥10%):

• Gastrointestinal: Diarrhea (15%), nausea (12%), vomiting (9%), heartburn.
• Systemic: Flushing, headache, fatigue.

Serious Adverse Reactions (Require Immediate Discontinuation):

• Hypersensitivity Reactions: Anaphylaxis, angioedema (reported in 0.1% of patients), urticaria, angioedema of the face/throat.
• Hematologic: Lymphopenia (<400 cells/mm³ in ~5% of patients).
• Hepatic: Elevated transaminases; monitor liver function tests periodically.
• Neurologic/Psychiatric: Vision changes, ataxia, cognitive impairment, mood alterations.

Pharmacist Role: Educate patients on recognizing early signs of hypersensitivity (e.g., rash progressing to blistering) and advise immediate medical attention if symptoms arise.

6. Drug Interactions

• CYP Enzymes: Minimal hepatic metabolism; no significant CYP3A4/2D6 interactions.
• P-glycoprotein Substrates: Potential for interactions with drugs like digoxin or cyclosporine (monitor if co-administered).
• Antacids/Proton Pump Inhibitors (PPIs): May reduce DMF absorption; separate administration by 2 hours.
• Immunosuppressants: Caution with concurrent use of corticosteroids or biologics due to additive immunosuppression.

Recommendation: Review all concomitant medications, including OTC products and supplements (e.g., St. John’s wort may reduce efficacy via CYP induction).

7. Contraindications and Precautions

• Absolute Contraindications:
  • Hypersensitivity to DMF, dimethyl fumarate, or its excipients.
  • History of severe allergic reactions (e.g., anaphylaxis).
• Relative Contraindications:
  • Severe hepatic impairment (monitor ALT/AST regularly).
  • Pregnancy/lactation (see below).

8. Special Populations

Pregnancy and Lactation:

• FDA Pregnancy Category C: Limited human data; animal studies show fetal harm.
• Recommendation: Use only if benefits outweigh risks. Advise breastfeeding mothers to take the dose 4–5 hours post-administration to minimize infant exposure. Monitor neonates for flushing, diarrhea, or vomiting.

Renal/Hepatic Impairment:

• No dose adjustment required; however, monitor liver enzymes in patients with pre-existing hepatic disease.

9. Storage and Stability

• Store at 15–30°C (59–86°F); protect from light. Avoid freezing.
• Shelf life: Typically 2–3 years from manufacturing date.

10. Clinical Recommendations for Pharmacists

• Patient Counseling:
  • Emphasize adherence to titration schedules and hydration to mitigate GI effects.
  • Advise on sun protection (photosensitivity reported in 5% of patients).
• Monitoring:
  • Baseline and periodic assessments: CBC, liver enzymes, renal function, and vision (risk of optic neuritis).
  • Screen for depression/anxiety due to CNS effects.
• Drug Utilization Review:
  • Check for overlapping immunosuppressants or hepatotoxic agents.

11. Conclusion

Dimethyl fumarate is a cornerstone therapy in RRMS and CIS, offering both immunomodulatory and neuroprotective benefits. Pharmacists play a critical role in optimizing its use through patient education, adverse effect monitoring, and coordination with prescribers to ensure safe and effective treatment. Staying updated on evolving guidelines (e.g., AAN 2023 recommendations) is essential for evidence-based care.

References:

• Meissner et al. (2015). NEJM; ORATORIO Trial (2018).
• FDA Labeling (2023).
• American Academy of Neurology Guidelines (2023).

This structured approach ensures pharmacists can provide actionable, patient-centered care while aligning with current standards in MS management.